Innovent Biologics, Inc.

Innovent Biologics, Inc. is a biopharmaceutical company headquartered in Suzhou Industrial Park, Jiangsu, China. The company's core business involves the discovery, development, manufacturing, and commercialization of high-quality medicines. Its mission is to empower patients worldwide with affordable, high-quality biopharmaceuticals.

Innovent Biologics focuses on major therapeutic areas including oncology, cardiovascular and metabolism, autoimmune diseases, and ophthalmology. The company has a portfolio of 18 products on the market, with key offerings such as TYVYT® (sintilimab), Mazdutide (a GLP-1/glucagon dual agonist), SYCUME® (teprotumumab), SINTBILO® (tafolecimab), and PECONDLE® (picankibart). Innovent operates a vertically integrated model encompassing discovery, clinical development, manufacturing, and commercialization.

Led by Founder, Chairman, and CEO Dr. Michael Yu, Innovent Biologics has established itself as a leading biopharmaceutical company in China with expanding global ambitions. The company reported product revenue exceeding RMB3.8 billion in Q1 2026, marking a year-on-year increase of over 50%, and achieved its first full year of net profit in 2025. Innovent is actively advancing several high-potential drug candidates into or towards global Phase 3 multi-regional clinical trials and has formed significant partnerships with international pharmaceutical companies like Takeda and Eli Lilly.